GlassScriptPhysician profile
Nicolette Orsky
NPI 1538724992
$3,202.01
in general payments reported to CMS, 2019-2025
22 companies · $1,378 in 2025
The $1,378 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $89.52 · 2022: $138 · 2023: $604 · 2024: $993 · 2025: $1,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,886 · Education: $88.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,885.63 |
| Education | $88.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,084.06 | 2021-2025 | |
| Janssen Biotech, INC. | $560.59 | 2022-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $291.24 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $273.09 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $109.16 | 2023-2025 | |
| Lilly USA, LLC | $96.87 | 2024-2025 | Omvoh |
| Alnylam Pharmaceuticals INC. | $90.72 | 2023-2025 | Givlaari |
| Ardelyx, INC. | $86.33 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $85.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.34 | 2022-2024 | Xifaxan |
| Aimmune Therapeutics, INC. | $69.96 | 2025 | Zenpep, Vowst |
| Gilead Sciences, INC. | $65.72 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $64.66 | 2024-2025 | Iqirvo, Bylvay |
| Regeneron Healthcare Solutions, INC. | $51.22 | 2024-2025 | Dupixent |
| Celgene Corporation | $39.50 | 2022-2023 | Zeposia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $38.51 | 2024 | Dificid |
| Qol Medical, LLC | $33.14 | 2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $22.54 | 2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $22.25 | 2025 | |
| Braintree Laboratories, INC. | $16.09 | 2023 | Sutab |
| Lucid Diagnostics INC. | $14.67 | 2023 | |
| Celltrion USA INC. | $13.74 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolette Orsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.